Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergan, Inc.
Allergan Comments on Today’s Follow up by the U.S. Food and Drug Administration FDA to Its Early Communication, Concluding the Agency’s Safety Review of Botulinum Toxins
May 22nd, 2009
Allergan, Inc. (NYSE: AGN) today provided a further clarification on the U.S. Food and Drug Administration’s (FDA) conclusion to its “Early Communication” regarding a safety review of botulinum toxins in the United States. On February 8, 2008, the FDA announced in an “Early Communication” that it was reviewing certain serious adverse events following the use of botulinum toxins. At the time, the FDA hosted a public teleconference, explaining that the review involved only a “relative handful of serious adverse events” and that the primary focus of the adverse events and the FDA’s review of them related to the therapeutic use of BOTOX® to treat juvenile cerebral palsy and...
Source: Health Business Week (2009-05-22)
|
